Cargando…

Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands

[Image: see text] Immunotherapy is considered a promising approach for cancer treatment. An important strategy for cancer immunotherapy is the use of cancer vaccines, which have been widely used for cancer treatment. Despite the great potential of cancer vaccines for cancer treatment, their therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rostamizadeh, Leila, Molavi, Ommoleila, Rashid, Mohsen, Ramazani, Fatemeh, Baradaran, Behzad, Lavasanaifar, Afsaneh, Lai, Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tabriz University of Medical Sciences (TUOMS Publishing Group) 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124882/
https://www.ncbi.nlm.nih.gov/pubmed/35677663
http://dx.doi.org/10.34172/bi.2022.23896
_version_ 1784711823710224384
author Rostamizadeh, Leila
Molavi, Ommoleila
Rashid, Mohsen
Ramazani, Fatemeh
Baradaran, Behzad
Lavasanaifar, Afsaneh
Lai, Raymond
author_facet Rostamizadeh, Leila
Molavi, Ommoleila
Rashid, Mohsen
Ramazani, Fatemeh
Baradaran, Behzad
Lavasanaifar, Afsaneh
Lai, Raymond
author_sort Rostamizadeh, Leila
collection PubMed
description [Image: see text] Immunotherapy is considered a promising approach for cancer treatment. An important strategy for cancer immunotherapy is the use of cancer vaccines, which have been widely used for cancer treatment. Despite the great potential of cancer vaccines for cancer treatment, their therapeutic effects in clinical settings have been limited. The main reason behind the lack of significant therapeutic outcomes for cancer vaccines is believed to be the immunosuppressive tumor microenvironment (TME). The TME counteracts the therapeutic effects of immunotherapy and provides a favorable environment for tumor growth and progression. Therefore, overcoming the immunosuppressive TME can potentially augment the therapeutic effects of cancer immunotherapy in general and therapeutic cancer vaccines in particular. Among the strategies developed for overcoming immunosuppression in TME, the use of toll-like receptor (TLR) agonists has been suggested as a promising approach to reverse immunosuppression. In this paper, we will review the application of the four most widely studied TLR agonists including agonists of TLR3, 4, 7, and 9 in cancer immunotherapy.
format Online
Article
Text
id pubmed-9124882
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Tabriz University of Medical Sciences (TUOMS Publishing Group)
record_format MEDLINE/PubMed
spelling pubmed-91248822022-06-07 Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands Rostamizadeh, Leila Molavi, Ommoleila Rashid, Mohsen Ramazani, Fatemeh Baradaran, Behzad Lavasanaifar, Afsaneh Lai, Raymond Bioimpacts Review [Image: see text] Immunotherapy is considered a promising approach for cancer treatment. An important strategy for cancer immunotherapy is the use of cancer vaccines, which have been widely used for cancer treatment. Despite the great potential of cancer vaccines for cancer treatment, their therapeutic effects in clinical settings have been limited. The main reason behind the lack of significant therapeutic outcomes for cancer vaccines is believed to be the immunosuppressive tumor microenvironment (TME). The TME counteracts the therapeutic effects of immunotherapy and provides a favorable environment for tumor growth and progression. Therefore, overcoming the immunosuppressive TME can potentially augment the therapeutic effects of cancer immunotherapy in general and therapeutic cancer vaccines in particular. Among the strategies developed for overcoming immunosuppression in TME, the use of toll-like receptor (TLR) agonists has been suggested as a promising approach to reverse immunosuppression. In this paper, we will review the application of the four most widely studied TLR agonists including agonists of TLR3, 4, 7, and 9 in cancer immunotherapy. Tabriz University of Medical Sciences (TUOMS Publishing Group) 2022 2022-03-26 /pmc/articles/PMC9124882/ /pubmed/35677663 http://dx.doi.org/10.34172/bi.2022.23896 Text en https://creativecommons.org/licenses/by-nc/4.0/ This work is published by BioImpacts as an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Review
Rostamizadeh, Leila
Molavi, Ommoleila
Rashid, Mohsen
Ramazani, Fatemeh
Baradaran, Behzad
Lavasanaifar, Afsaneh
Lai, Raymond
Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands
title Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands
title_full Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands
title_fullStr Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands
title_full_unstemmed Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands
title_short Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands
title_sort recent advances in cancer immunotherapy: modulation of tumor microenvironment by toll-like receptor ligands
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124882/
https://www.ncbi.nlm.nih.gov/pubmed/35677663
http://dx.doi.org/10.34172/bi.2022.23896
work_keys_str_mv AT rostamizadehleila recentadvancesincancerimmunotherapymodulationoftumormicroenvironmentbytolllikereceptorligands
AT molaviommoleila recentadvancesincancerimmunotherapymodulationoftumormicroenvironmentbytolllikereceptorligands
AT rashidmohsen recentadvancesincancerimmunotherapymodulationoftumormicroenvironmentbytolllikereceptorligands
AT ramazanifatemeh recentadvancesincancerimmunotherapymodulationoftumormicroenvironmentbytolllikereceptorligands
AT baradaranbehzad recentadvancesincancerimmunotherapymodulationoftumormicroenvironmentbytolllikereceptorligands
AT lavasanaifarafsaneh recentadvancesincancerimmunotherapymodulationoftumormicroenvironmentbytolllikereceptorligands
AT lairaymond recentadvancesincancerimmunotherapymodulationoftumormicroenvironmentbytolllikereceptorligands